Final overall survival for the phase III, KEYNOTE-811 study of pembrolizumab plus trastuzumab and chemotherapy for HER2+advanced, unresectable or metastatic G/GEJ adenocarcinoma
Rha, S., Kawazoe, A., Bai, Y., Xu, J., Lonardi, S., Metges, J.,…Tabernero, J., …Janjigian, Y. (2024). Final overall survival for … Read More
